
Does JPM week actually predict the year ahead in biopharma? Locust Walk analyzed multi-year data across licensing, M&A, and capital markets.
Takeaway: JPM is a strong signal for licensing momentum, but not for M&A or deal value trends.
Full analysis: lnkd.in/eFHH6mCJ

English










